Table 1.

Overview H3K36me3-associated regulators in different cancers

Cancer subtype	Signaling pathway	Category	Mechanism	Function	Role
Colorectal cancer	Wnt/β-catenin signaling pathway	KDM4C: overexpression	Upregulating MALAT1 expression	Metastasis	Promoter
		SETD2: mutation	Aberrant Dvl2 alternative splicing	Tumorigenesis	Suppressor
Liver cancer	AP-1 pathway	SETD2: mutation	Dysregulated cholesterol homeostasis	Tumorigenesis	Suppressor
			P53 inhibition
Pancreatic cancer	/	SETD2: mutation	Promoting acinar-to-ductal transition	Transformation	Suppressor
				Progression
Lung cancer	CXCL1-associated signaling pathway	SETD2: mutation	Aberrant FGFR-2 gene alternative splicing	Tumorigenesis	Promoter
			CXCL1-mediated activation of cell cycle	Proliferation	Suppressor
			P53 inactivation	metastasis
			Dysregulation of gene expression	Prognosis
Breast cancer	/	SETD2: mutation	Unstrained expression of oncogenes	Metastasis	Suppressor
		H3 mutation		Prognosis
Renal cancer	Wnt/β-catenin signaling pathway	SETD2: mutation; loss	Genome reprogramming	Tumorigenesis	Suppressor
			Defective DNA methylation	Prognosis
			Defective DSBs repair
			P53 inhibition
Pediatric cancer	/	H3F3A/H3F3B: mutation	Histone methylation reprogramming	Transformation	Suppressor
		SETD2: mutation; loss	Upregulation of oncogenes	Tumorigenesis	Promoter?
			Impair MMR
Prostate cancer	AMPK signaling pathway	SETD2: mutation	Altering histone methylation landscape	Progression	Suppressor
Hematological malignant tumor	/	SETD2: mutation	Dysregulation and malignant transformation of hematopoietic stem cells	Tumorigenesis	Suppressor

This table lists the role of H3K36me3-associated epigenetic regulators in different cancer types, including their genetic alternations, related cellular signaling pathways, and which stage of cancer processes their predominantly affect. Pediatric cancer refers to glioblastoma, chondroblastoma, giant cell tumors of bone. The symbol “/” means unknown